Human Drug Off-label Veterinary Use in U.S., By Application (Sedatives/Analgesics and Oncology)
Table of Contents
Chapter 1. Human Drug Off-label Veterinary Use in U.S. Estimates, by Application (2024)
1.1. Sedation/Analgesia
1.1.1. Key Parameters Covered (for each drug mentioned below) -
1.1.1.1. Drug Name
1.1.1.2. Strength
1.1.1.3. Vial Volume
1.1.1.4. Estimated Revenue 2024 (USD Million)
1.1.1.5. Estimated Sale Volume 2024 (Units)
1.1.2. Key Drugs Covered -
1.1.2.1. Buprenorphine
1.1.2.2. Diazepam
1.1.2.3. Propofol
1.1.2.4. Butorphanol
1.1.2.5. Dexmedetomidine
1.1.2.6. Fentanyl
1.1.2.7. Hydromorphone
1.1.2.8. Methadone
1.2. Oncology
1.2.1. Key Parameters Covered (for each drug mentioned below) -
1.2.1.1. Drug Name
1.2.1.2. Strength
1.2.1.3. Vial Volume
1.2.1.4. Estimated Revenue 2024 (USD Million)
1.2.1.5. Estimated Sale Volume 2024 (Units)
1.2.2. Key Drugs Covered -
1.2.2.1. Carboplatin
1.2.2.2. Doxorubicin
1.2.2.3. Vinblastine
1.2.2.4. Vincristine
1.2.2.5. Chlorambucil
1.2.2.6. Cyclophosphamide
1.2.2.7. Lomustine
Chapter 2. Industry Outlook
2.1. Market Driver Analysis
2.2. Market Restraint Analysis
2.3. Market Opportunity Analysis
2.4. Market Challenge Analysis
2.5. Regulatory Landscape
2.6. Business Activities
2.6.1. Product Launch
2.6.2. Mergers & Acquisitions
2.6.3. Partnerships & Collaborations
2.6.4. Expansion
2.6.5. Others (recognition, product recall, etc.)
ISO 9001:2015 & 27001:2022 Certified
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
Trusted market insights - try a free sample
See how our reports are structured and why industry leaders rely on Grand View Research. Get a free sample or ask us to tailor this report to your needs.
